Marizyme, INC

Marizyme, Inc. has entered into an assignment for the benefit of creditors, effectively initiating a liquidation of all company assets.

Marizyme, Inc. announced that it will restate its financial statements for the quarterly periods ended March 31, 2024, and June 30, 2024, due to material misstatements related to debt/equity transactions.

Marizyme, Inc. has entered into a promissory note agreement with Qualigen Therapeutics, Inc., securing a $1.25 million loan with an 18% annual interest rate.

Marizyme, Inc. has received FDA 510(k) clearance for its DuraGraft product to be stored at controlled room temperatures, eliminating the need for refrigerated storage.

Julie Kampf resigned from Marizyme Inc.'s board of directors, effective January 31, 2024.

Marizyme, Inc.'s Q3 2024 results reveal a net loss and highlight substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.

Marizyme Inc. reported a decrease in revenue and a net loss for the second quarter of 2024, primarily due to financial constraints impacting production and operations.

Marizyme Inc. reported a net loss of $6.2 million for the first quarter of 2024, with a significant decrease in revenue compared to the same period last year, highlighting ongoing financial challenges.

Marizyme, Inc. restated its 2023 financial statements due to errors in convertible note accounting and identified a material weakness in its internal controls over financial reporting.

Marizyme, Inc.'s 10-K filing provides a comprehensive overview of the company's securities, financial performance, and strategic direction, highlighting its focus on DuraGraft commercialization and other medical technologies.